Medications for Both Depression and Anxiety
Start with SSRIs (selective serotonin reuptake inhibitors) or SNRIs (serotonin-norepinephrine reuptake inhibitors) as first-line pharmacotherapy for treating both depression and anxiety. These second-generation antidepressants are effective for both conditions and should be your primary pharmacological choice 1.
First-Line Medication Options
The following medications treat both depression and anxiety effectively:
SSRIs (Preferred First-Line)
- Citalopram
- Escitalopram
- Fluoxetine
- Paroxetine
- Sertraline
- Fluvoxamine
SNRIs (Alternative First-Line)
- Venlafaxine
- Duloxetine
Other Second-Generation Antidepressants
- Mirtazapine - particularly useful when anxiety symptoms are prominent at treatment initiation, as it provides early relief of anxiety through 5-HT2 receptor blockade without the initial jitteriness that SSRIs can cause 2
- Bupropion
Evidence Quality and Rationale
The American College of Physicians guideline establishes that no clinically significant differences exist between individual SSRIs or between SSRIs and SNRIs in treating depression 1. While some meta-analyses show statistically significant differences (e.g., escitalopram vs. citalopram), the effect sizes are small and not clinically meaningful 1.
Critical point about anxiety symptoms: Anxiety is present in up to 96% of patients with depression, and somatic anxiety symptoms occur in up to 86% of depressed patients 2. Treating both simultaneously is essential, as patients with comorbid anxiety and depression have worse outcomes, greater functional impairment, and higher suicide risk 3, 2.
Dosing Considerations for Comorbid Anxiety
When treating anxiety disorders alongside depression, higher doses of SSRIs may be required compared to depression alone, and onset of action may be slower 4. This is particularly true for panic disorder and OCD.
Important Caveats
Initial Anxiety Worsening
SSRIs and SNRIs can transiently increase anxiety symptoms when first started, manifesting as jitteriness, agitation, insomnia, and gastrointestinal symptoms 2. This is why mirtazapine may be advantageous in highly anxious patients, as it was superior to both citalopram and paroxetine in alleviating anxiety symptoms early in treatment 2.
What NOT to Use First-Line
Benzodiazepines should not be first-line monotherapy for comorbid anxiety and depression, as they are ineffective for long-term depression treatment 5. However, they may be added short-term to SSRIs/SNRIs for rapid anxiety relief while waiting for antidepressant effects, particularly in patients with severe anxiety 3.
Pharmacotherapy alone is not recommended as first-line treatment - cognitive behavioral therapy (CBT) or behavioral activation should be prioritized when available 6. However, in real-world practice where mental health resources are limited, starting an SSRI/SNRI is appropriate.
Treatment Algorithm
- Start an SSRI or SNRI (choose based on side effect profile and patient preference)
- If high baseline anxiety/agitation: Consider mirtazapine to avoid initial anxiety worsening
- If inadequate response at 4-6 weeks: Increase dose (may need higher doses for anxiety component)
- If partial response with residual anxiety: Consider adding short-term benzodiazepine or switching to different SSRI/SNRI
- Continue treatment 4-9 months after response for first episode; longer for recurrent episodes 1
Medication Selection Factors
Choose pharmacotherapy when:
- Mental health resources unavailable
- Patient previously responded well to medication
- Severe neurovegetative symptoms present
- Patient preference 6
The evidence strongly supports that all SSRIs and SNRIs work through similar mechanisms for both anxiety and depression (increasing synaptic serotonin), making them rational choices for comorbid presentations 4.